Sign up
Pharma Capital

Bioasis Technologies to meet with FDA June 2019 on it xB3 platform technology

Bioasis Technologies Inc. (OTCQB:BIOAF) (TSX.V:BTI) Director, President & CEO Dr. Mark Day sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The Connecticut based biopharmaceutical company is developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.


View full BIOAF profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.